GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » OptimizeRx Corp (NAS:OPRX) » Definitions » Piotroski F-Score

OptimizeRx (OptimizeRx) Piotroski F-Score : 2 (As of Apr. 28, 2024)


View and export this data going back to 2009. Start your Free Trial

What is OptimizeRx Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

OptimizeRx has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for OptimizeRx's Piotroski F-Score or its related term are showing as below:

OPRX' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 8
Current: 2

During the past 13 years, the highest Piotroski F-Score of OptimizeRx was 8. The lowest was 2. And the median was 4.


OptimizeRx Piotroski F-Score Historical Data

The historical data trend for OptimizeRx's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptimizeRx Piotroski F-Score Chart

OptimizeRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 2.00 8.00 5.00 2.00

OptimizeRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 5.00 4.00 2.00

Competitive Comparison of OptimizeRx's Piotroski F-Score

For the Health Information Services subindustry, OptimizeRx's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OptimizeRx's Piotroski F-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, OptimizeRx's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where OptimizeRx's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -6.398 + -4.161 + -2.865 + -4.141 = $-17.57 Mil.
Cash Flow from Operations was -0.086 + -2.368 + 1.473 + -6.257 = $-7.24 Mil.
Revenue was 13.003 + 13.818 + 16.331 + 28.369 = $71.52 Mil.
Gross Profit was 7.433 + 7.825 + 9.8 + 17.841 = $42.90 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(134.651 + 131.693 + 121.325 + 123.929 + 183.374) / 5 = $138.9944 Mil.
Total Assets at the begining of this year (Dec22) was $134.65 Mil.
Long-Term Debt & Capital Lease Obligation was $34.60 Mil.
Total Current Assets was $54.33 Mil.
Total Current Liabilities was $17.88 Mil.
Net Income was -3.761 + -3.885 + -3.467 + -0.326 = $-11.44 Mil.

Revenue was 13.732 + 13.979 + 15.086 + 19.654 = $62.45 Mil.
Gross Profit was 8.102 + 8.99 + 9.421 + 12.454 = $38.97 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(140.985 + 138.139 + 147.448 + 135.873 + 134.651) / 5 = $139.4192 Mil.
Total Assets at the begining of last year (Dec21) was $140.99 Mil.
Long-Term Debt & Capital Lease Obligation was $0.15 Mil.
Total Current Assets was $98.58 Mil.
Total Current Liabilities was $8.40 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

OptimizeRx's current Net Income (TTM) was -17.57. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

OptimizeRx's current Cash Flow from Operations (TTM) was -7.24. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-17.565/134.651
=-0.13044834

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-11.439/140.985
=-0.08113629

OptimizeRx's return on assets of this year was -0.13044834. OptimizeRx's return on assets of last year was -0.08113629. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

OptimizeRx's current Net Income (TTM) was -17.57. OptimizeRx's current Cash Flow from Operations (TTM) was -7.24. ==> -7.24 > -17.57 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=34.602/138.9944
=0.24894528

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=0.145/139.4192
=0.00104003

OptimizeRx's gearing of this year was 0.24894528. OptimizeRx's gearing of last year was 0.00104003. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=54.331/17.881
=3.0384766

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=98.577/8.396
=11.74094807

OptimizeRx's current ratio of this year was 3.0384766. OptimizeRx's current ratio of last year was 11.74094807. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

OptimizeRx's number of shares in issue this year was 17.777. OptimizeRx's number of shares in issue last year was 17.153. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=42.899/71.521
=0.59980985

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=38.967/62.451
=0.62396119

OptimizeRx's gross margin of this year was 0.59980985. OptimizeRx's gross margin of last year was 0.62396119. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=71.521/134.651
=0.53115833

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=62.451/140.985
=0.44296202

OptimizeRx's asset turnover of this year was 0.53115833. OptimizeRx's asset turnover of last year was 0.44296202. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+0+1
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

OptimizeRx has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

OptimizeRx  (NAS:OPRX) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


OptimizeRx Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of OptimizeRx's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


OptimizeRx (OptimizeRx) Business Description

Traded in Other Exchanges
N/A
Address
400 Water Street, Suite 200, Rochester, MI, USA, 48307
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Executives
Marion Odence-ford officer: General Counsel and CCO 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Theresa Greco officer: Chief Commercial Officer 260 CHARLES STREET, SUITE 302, WALTHAM MA 02153
Doug Besch officer: Chief Product Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
William J Febbo officer: Chief Executive Officer 600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
James Paul Lang director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Stephen L Silvestro officer: Chief Commercial Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Ellen O'connor Vos director C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Edward Stelmakh officer: COO and CFO 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Miriam J Paramore officer: President 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Patrick D Spangler director, officer: SVP of Product & Strategy 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Douglas P Baker officer: Chief Financial Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Todd Inman officer: Chief Technology Officer 400 WATER STREET, SUITE 200, ROCHESTER MI 48307
Gregory D Wasson director 200 WILMOT ROAD, DEERFIELD IL 60015
Gus D Halas director 38 PHEASANT RUN PLACE, DANVILLE CA 94506
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022